

**EPHMRA**  
**ANATOMICAL CLASSIFICATION**  
**GUIDELINES 2021**

**Section B**


**Changed Classes/Guidelines**

**Final Version**

**Date of issue: 19<sup>th</sup> December 2020**

<b>A2B</b>	<b>ANTIULCERANTS</b>  Combinations of specific antiulcerants with other substances, such as anti-infectives against <i>Helicobacter pylori</i> , antispasmodics, gastroprokinetics, that are for ulcers, gastro-oesophageal reflux disease or similar conditions are classified according to the antiulcerant substance. For example, proton pump inhibitors in combination with these anti-infectives are classified in A2B2. Combinations of antiulcerants with non-steroidal anti-inflammatories where the antiulcerant is present for gastric protection are classified in M1A1.	r2020
A2B1	<b>H2 antagonists</b>  Includes, for example, cimetidine, famotidine, nizatidine, ranitidine, roxatidine. Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6.	R2002
A2B2	<b>Proton pump inhibitors</b>  Includes esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole. Combinations of proton pump inhibitors with gastroprokinetics for ulcers, gastro-oesophageal disease or similar conditions are classified here. Includes potassium-competitive acid blockers (P-CABs) such as revaprazan, tegoprazan, vonoprazan, etc.	r2021
A2B3	<b>Prostaglandin antiulcerants</b>  Includes misoprostol, enprostil.	
A2B4	<b>Bismuth antiulcerants</b>  Includes combinations with antacids.	
A2B9	<b>All other antiulcerants</b>  Includes all other products containing substances with antiulcerant action where the type of substance is not specified in classes A2B1 to A2B4. Combinations of antiulcerants with antispasmodics are classified in A2B1 to A2B9 according to the type of antiulcerant. Combinations of low dose H2 antagonists with antacids are classified with antacids in A2A6. Included are, eg carbenoxolone, gefarnate, pirenzepine, proglumide, sucralfate and sofalcone. Herbal combinations are classified in A2X.  In Japan, Korea and Taiwan only, sulpiride and other psycholeptics indicated for ulcer use are also included in this group, whilst in all other countries, these compounds are classified in N5A9.  Products containing rebamipide for gastric mucosal protection are classified here. Products containing rebamipide and indicated for dry eye are classified in S1K9.	r2020
<b>A2C</b>	Out of use	D2018

<b>A11B</b>	<b>MULTIVITAMINS WITHOUT MINERALS</b>	R2003
	Includes all multivitamin combinations as defined under A11A but without minerals, except all oral preparations containing procaine (see A13A1). Products for general well-being are classified in A13A.	
A11B1	<b>Prenatal</b>	R1993
	Includes those products specifically indicated for vitamin supplementation during pregnancy or lactation.	
A11B2	<b>Paediatric</b>	
	Analogous to A11A2 but without minerals.	
A11B3	GERIATRIC	
	Analogous to A11A3 but without minerals (see also A14A2).	
A11B4	<b>Other multivitamins without minerals</b>	
<b>A11C</b>	<b>VITAMIN A AND D, INCLUDING COMBINATIONS OF THE TWO</b>	
A11C1	<b>Vitamin A</b>	
	Includes combinations of vitamin A with vitamin E, but excludes combinations of vitamin A with vitamin D (see A11C3).	
A11C2	<b>Vitamin D</b>	r2021
	Excludes combinations of vitamin D with vitamin A (see A11C3).	
	Products containing vitamin D or its analogues with multiple indications are classified here. Products only for secondary hyperparathyroidism are classified in H4F. Cinacalcet is classified in H4F.	
	Products containing vitamin D that are mainly for vitamin D deficiency but also contain minerals (for example, magnesium) are classified here. Products containing both vitamin D and calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified in A12A.	
	Products containing vitamin D with vitamin E (with and without minerals) are classified here. Products containing vitamin D with vitamin E and with calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified in A12A.	
A11C3	<b>Combinations of vitamin A with vitamin D</b>	R2003
	Products containing halibut or cod liver oil are included in this group. Combinations of vitamin A and/or vitamin D with other vitamins are classified as multivitamins in A11A or A11B.	



A11X9	<p><b>All other vitamins, plain and in combination</b></p> <p>Includes all other vitamin products such as pantothenic acid, riboflavine (vitamin B2) and para-aminobenzoic acid (PABA). Vitamin K is classified in B2B, and vitamin P in C5C.</p> <p>Includes all vitamin B combinations without vitamin B1 when they do not contain vitamin A or vitamin D.</p> <p>Vitamin B2 with vitamin B6 is classified here.</p> <p>Vitamin B1 with vitamin B2 is classified in A11D9.</p> <p>Products containing vitamin D that are mainly for vitamin D deficiency but also contain minerals (for example, magnesium) are classified in A11C2. Products containing both vitamin D and calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified in A12A.</p> <p>Products containing vitamin D in combination with vitamin E (with and without minerals) are classified in A11C2. Products containing vitamin D with vitamin E and with calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified in A12A.</p>	r2021
-------	---	-------

<b>A12</b>	<b>MINERAL SUPPLEMENTS</b>	
<b>A12A</b>	<p><b>CALCIUM PRODUCTS</b></p> <p>Includes single and combination products promoted for osteoporosis or calcium deficiency, even when indicated for other diseases as well (see A11G2 and A11A4). See also M5B.</p> <p>Products containing both calcium and magnesium to treat deficiency of these minerals are classified here.</p> <p>Products containing calcium and indicated for both hyperphosphataemia and calcium deficiency are classified in V3G2.</p> <p>Products containing both vitamin D and calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified here. Products containing vitamin D with vitamin E and with calcium (with and without other minerals) for osteoporosis or calcium deficiency are classified here.</p>	r2021
<b>A12B</b>	<p><b>POTASSIUM PRODUCTS</b></p> <p>Potassium diuretic combinations are classified in C3 (see note under A12C regarding potassium aspartate).</p>	
<b>A12C</b>	<p><b>OTHER MINERAL SUPPLEMENTS</b></p> <p>Includes magnesium and/or fluoride products used as alimentary supplements. Potassium and magnesium aspartate are usually indicated in the treatment of cardiac disease and should be classified in C6X. In certain cases, however, when these compounds are indicated as mineral supplements, they should be classified in A12.</p> <p>Products containing both calcium and magnesium to treat deficiency of these minerals are classified in A12A.</p>	r2017
A12C1	<b>Magnesium supplements</b>	R1993
A12C2	<b>Other mineral supplements</b>	

<b>A16</b>	<b>OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</b>	
<b>A16A</b>	<p data-bbox="316 203 1401 237"><b>OTHER ALIMENTARY TRACT AND METABOLISM PRODUCTS</b></p> <p data-bbox="316 277 1401 349">Includes all alimentary tract and metabolism products not classified elsewhere. Oral preparations containing procaine are classified in A13A1.</p> <p data-bbox="316 389 1401 495">Products containing one or more oral antidiabetic substances in combination with one or more substances from a cardiovascular class where the aim is to treat both the diabetes and the cardiovascular condition are classified in A10X1.</p> <p data-bbox="316 535 1401 568">Products containing teduglutide for short bowel syndrome are classified here.</p> <p data-bbox="316 609 1401 734">Products containing elapegademase or pegademase for severe combined immunodeficiency disease (SCID) associated with a deficiency of adenosine deaminase are classified in L3A9.</p>	r2021

<b>B2D</b>	<b>BLOOD COAGULATION</b>	
B2D1	<b>Factor VIII, including substitutes</b>  Includes antihaemophilic globulin A, emcizumab, etc. Products containing von Willebrand factor only are classified in B2D9.	r2019
B2D2	<b>Factors II, VII, IX and X</b>  Includes antihaemophilic globulin B and prothrombin complex.	
B2D3	<b>Anti-inhibitor-coagulation complex</b>  Includes aPCC (activated prothrombin complex concentrate), activated FVII (FVIIa), and eptacog alfa.	R2003
B2D4	<b>Factor XIII</b>	
B2D5	<b>Fibrinogen</b>	
B2D6	<b>Fresh frozen plasma and antihaemophilic plasma</b>	
B2D7	<b>Cohn-Fraction I</b>	
B2D8	<b>Platelet concentrates</b>	
B2D9	<b>Other blood fractions</b>  Includes products containing von Willebrand factor (single ingredient).	R2005
<b>B2E</b>	<b>THROMBOPOIETIN AGONISTS</b>  Includes products containing thrombopoietin agonists, such as eltrombopag and romiplostim.  Products containing oprelvekin for the prevention of severe thrombocytopenia are classified in B6X.	r2021
<b>B2F</b>	<b>TISSUE SEALING PREPARATIONS</b>  Includes products imitating the physiological process of fibrin formation which are used for tissue sealing, haemostasis and support of wound healing. Products containing thrombin/collagen for the prevention of bleeding prior to implantation of ICDs/pacemakers are classified here.	r2016
<b>B2G</b>	<b>SYSTEMIC HAEMOSTATICS</b>  Tissue extracts with haemostatic activity, and including snake venoms causing blood clotting, and hormone products exclusively promoted as haemostatics. Includes products containing parenteral conjugated oestrogens for control of uterine bleeding.	r2019



<b>B6</b>	<b>ALL OTHER HAEMATOLOGICAL AGENTS</b>	R1996
<b>B6A</b>	Out of use; can be reused from 1999.	D1996
<b>B6B</b>	<b>HYALURONIDASE</b>	
<b>B6C</b>	Out of use	D2020
<b>B6D</b>	<b>HEREDITARY ANGIOEDEMA PRODUCTS</b>	I2015
	Includes products containing eg C1 inhibitor/conestat alfa, ecallantide, icatibant, etc when indicated for hereditary angioedema.	
<b>B6X</b>	<b>OTHER HAEMATOLOGICAL AGENTS</b>	r2021
	Includes haemins. Excluded are those preparations used in the treatment of veins and haemorrhoids (C5) and preparations for dermatological use (D3A).	
	Products containing oprelvekin for the prevention of severe thrombocytopenia are classified here.	

<p><b>C1D</b></p>	<p><b>CORONARY THERAPY EXCLUDING CALCIUM ANTAGONISTS AND NITRITES</b></p> <p>This group includes all other products indicated for coronary insufficiency and angina pectoris. It includes benziodarone, capobenic acid, carbocromen, cinepazet, cinepazic acid, cloridarol, dilazep, dipyridamole, efloxate, etafenone, fenalcomine, flosequinan, hexobendine, imolamine, ivabradine, medibazine, molsidomine, oxyfedrin, trimetazidine, visnadine. Combinations with nitrites are included in C1E and with beta-blockers are included in C7B.</p>	<p>R2007</p>
<p><b>C1E</b></p>	<p><b>NITRITES AND NITRATES</b></p> <p>This group includes all nitrites and analogous products and combinations if they are indicated for angina pectoris. Combinations of nitrites with cardiac glycosides are classified in C1A2 and combinations with beta-blockers in C7B.</p>	
<p><b>C1F</b></p>	<p><b>POSITIVE INOTROPIC AGENTS</b></p> <p>This group includes substances such as amrinone, milrinone, fenoximone, piroximone, xamoterol.</p>	<p>R1994</p>
<p><b>C1X</b></p>	<p><b>ALL OTHER CARDIAC PREPARATIONS</b></p> <p>This group includes substances such as alprostadil, crateagus glycosides, creatinolphosphate, phosphocreatinine, levocarnitine and ubidecarenone. Combination products are only classified in this group if they contain a substance which is not in the C group.</p> <p>Products containing alprostadil for peripheral arterial occlusive disease only are classified in C4A1. Products containing alprostadil for erectile dysfunction only are classified in G4E9. Products containing alprostadil for patent ductus arteriosus only or for multiple indications are classified here.</p> <p>Products containing tafamidis for transthyretin amyloid polyneuropathy (TAP) only are classified in N7X. Products containing tafamidis for transthyretin amyloid cardiomyopathy (TAC) only are classified here. Products containing tafamidis for both TAP and TAC are classified in N7X.</p>	<p>r2021</p>

<b>C3</b>	<b>DIURETICS</b>	
<b>C3A</b>	<b>DIURETICS</b>	
	Combinations with potassium belong to C3A1, C3A2 or C3A3.	
<b>C3A1</b>	<b>Potassium-sparing agents plain</b>	
	This group includes all products containing amiloride, triamterene and spironolactone (canrenoic acid) plain.	
<b>C3A2</b>	<b>Loop diuretics plain</b>	r2008
	This group includes all products containing bumetanide, etacrynic acid, etozolin, furosemide, muzolimine, piretanide plain.	
<b>C3A3</b>	<b>Thiazides and analogues plain</b>	r2008
	This group includes all products containing thiazides, eg altizide, bendroflumethiazide, benzyhydrochlorothiazide, butizide, chlorothiazide, cyclopenthiiazide, flumethiazide, hydrochlorothiazide, mebutizide, paraflutizide, teclothiazide, trichlormethiazide and analogues (which act similar to thiazides) eg chlortalidone, clopamide, indapamide, mefruside, tienilic acid, xipamide, tripamide, metolazone, quinethazone, clorexolone and meticrane.	
<b>C3A4</b>	<b>Potassium-sparing agents with loop diuretic combinations</b>	
<b>C3A5</b>	<b>Potassium-sparing agents with thiazides and/or analogue combinations</b>	
<b>C3A6</b>	Out of use; can be reused from 2014.	D2011
<b>C3A7</b>	<b>Vasopressin receptor antagonist diuretics</b>	I2011
	Includes products containing vasopressin receptor antagonists such as conivaptan, mozavaptan and tolvaptan.	
<b>C3A9</b>	<b>Other diuretics</b>	r2021
	Includes eg carboanhydrase inhibitors such as clofenamide and diclofenamide (when not used for the treatment of glaucoma or primary periodic paralysis), diuretics of vegetable origin etc, ethoxazolamide, isosorbide, mannitol, chlorazanyl; mercury salts are also included in this group.	
	Products containing diclofenamide for primary periodic paralysis are classified in M5X. Products containing diclofenamide for glaucoma are classified in S1E1.	

<b>C4</b>	<b>CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS</b>	
<b>C4A</b>	<b>CEREBRAL AND PERIPHERAL VASOTHERAPEUTICS</b>	R2005
	This group includes all products (including citicoline) which are mainly recommended for cerebral vascular diseases or peripheral circulatory disorders excluding venous diseases. Combination products are only classified in this group if they do not belong to group C1-C3, C7-C11.	
<b>C4A1</b>	<b>Cerebral and peripheral vasotherapeutics excluding calcium antagonists with cerebral activity</b>	r2021
	Products containing phenoxybenzamine alone, and indicated either for hypertension or BPH are classified here. Products containing cinepazide alone and for vasodilation are classified here. Products containing beperminogene perplasmid for improvement of limb ischaemia are classified here. Products containing alprostadil for peripheral arterial occlusive disease only are classified here. Products containing alprostadil for erectile dysfunction only are classified in G4E9. Products containing alprostadil for patent ductus arteriosus only or for multiple indications are classified in C1X.	
<b>C4A2</b>	<b>Calcium antagonists with cerebral activity</b>	R1993
	Includes, bencyclane, cinnarizine, cyclandelate, flunarizine and nimodipine.	

<b>C10</b>	<b>LIPID-REGULATING/ANTI-ATHEROMA PREPARATIONS</b>  Excludes products intended for weight reduction.	R2005
<b>C10A</b>	<b>CHOLESTEROL AND TRIGLYCERIDE REGULATING PREPARATIONS</b>  Includes all products regulating cholesterol and triglycerides only. Combinations with products of group C4 should be classified here. Combinations with oral antidiabetic substances are classified in A10X1.	r2010
C10A1	<b>Statins (HMG-CoA reductase inhibitors)</b>  Includes atorvastatin, cerivastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin.  Combinations of statins with ezetimibe are classified in C10C.	R2006
C10A2	<b>Fibrates</b>  Includes bezafibrate, ciprofibrate, clofibrate, clofibril, etofibrate, fenofibrate, gemfibrozil, simfibrate.	I1997
C10A3	<b>Ion-exchange resins</b>  Includes cholestyramine, colestipol, polidexide.	I1997
C10A4	<b>PCSK9 inhibitors</b>  Includes proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, eg alirocumab, evolocumab.	I2016
C10A9	<b>All other cholesterol/triglyceride regulators</b>  Includes ezetimibe, probucol, tiadenol, pyridinolcarbamate and all other products excluding those in C10B.  Combinations of ezetimibe with statins or with bempedoic acid are classified in C10C.  Nicotinic acid derivatives if indicated in this area are classified here, eg acipimox.  Products containing volanesorsen for familial chylomicronaemia syndrome (FCS) are classified here.	r2021
<b>C10B</b>	<b>ANTI-ATHEROMA PREPARATIONS OF NATURAL ORIGIN</b>  This class includes products of natural origin used for the prevention and treatment of arteriosclerosis, eg omega-3 fatty acids, garlic preparations, lecithin.  Products containing omega-3 fatty acids for the reduction of triglycerides and/or for the prevention and treatment of arteriosclerosis are classified here. Products containing omega-3 fatty acids for other conditions or for multiple uses are	r2021

	classified in V3X.	
--	--------------------	--

<p><b>C10C</b></p>	<p><b>LIPID REGULATORS IN COMBINATION WITH OTHER LIPID REGULATORS</b></p> <p>Includes products containing two or more substances, all of which are lipid regulators. These are combinations of different types of lipid regulator in C10A. For example, products containing a statin in combination with nicotinic acid, or products containing a statin in combination with ezetimibe, are classified here.</p> <p>Products containing ezetimibe with bempedoic acid are classified here.</p> <p>Combinations of a statin with another statin are classified in C10A1. Combinations of a fibrate with another fibrate are classified in C10A2.</p> <p>Combinations of lipid regulators of natural origin with other lipid regulators of natural origin are classified in C10B.</p> <p>Combinations of a lipid regulating substance from C10A together with a substance from C10B (anti-atheroma preparations of natural origin) are also classified in C10C.</p> <p>Products containing one or more oral antidiabetic substances in combination with one or more substances from a cardiovascular class (C) are classified in A10X1. For example, a combination product containing pioglitazone with simvastatin is classified in A10X1.</p>	<p>r2021</p>
--------------------	---	--------------

<b>G1D</b>	<b>GYNAECOLOGICAL ANTISEPTICS</b>  Includes those products indicated for gynaecological conditions. Excluded are antiseptics for dermatological use which are classified in D8A and antiseptics for non-human use, which are classified in V5A.  Products containing dapivirine (vaginal ring) for the prevention of HIV transmission are classified here.	r2021
------------	--	-------



<b>G2</b>	<b>OTHER GYNAECOLOGICALS</b>	
<b>G2A</b>	<b>UTEROTONIC PRODUCTS</b>	r2019
	Includes products used to induce labour (including delivery of placenta) and/or to reduce postpartum haemorrhage. Includes oxytocics and prostaglandins E1 and E2, and products used for cervical dilatation.	
<b>G2B</b>	<b>TOPICAL CONTRACEPTIVES</b>	
<b>G2C</b>	Out of use; can be reused from 2000.	D1997
<b>G2D</b>	<b>PROLACTIN INHIBITORS</b>	R1999
	This group includes products used as prolactin inhibitors and containing bromocriptine, cabergoline, pergolide, quinagolide, terguride etc. Bromocriptine in lower doses (1 mg, 2.5 mg) for sexual disorders is classified here; higher doses for parkinsonism are in N4A. In Japan, bromocriptine is classified in N4A.	
<b>G2E</b>	<b>LABOUR INHIBITORS</b>	I1997
	This group includes products acting as labour inhibitors eg ritodrine.	
<b>G2F</b>	<b>TOPICAL SEX HORMONES</b>	r2021
	This group includes all topical hormones and/or steroids indicated for gynaecological conditions. Transdermal patches and vaginal formulations containing oestrogens and intended for a systemic effect are classified in G3C.	
	Products containing progesterone in topical form (such as gel) for relief of breast pain are classified here.	
<b>G2X</b>	<b>OTHER GYNAECOLOGICAL PRODUCTS</b>	I1997
<b>G2X1</b>	<b>Gynaecological antispasmodics</b>	I1997
	This group includes oral analgesics and antispasmodics indicated exclusively for dysmenorrhoea.	
<b>G2X9</b>	<b>Other gynaecologicals</b>	r2021
	Specific products included in this class are non-hormonal anti-inflammatories (eg benzydamine) which are indicated specifically to treat gynaecological conditions. Includes lubricants for intimate vaginal use only. Includes products (lactogogues) for the promotion of milk production.	
	Products containing paroxetine (7.5mg daily) and indicated for menopausal vasomotor symptoms are classified here.	
	Products containing bremelanotide or flibanserin and indicated for hypoactive sexual desire disorder (HSDD) in women are classified here.	

Products containing omega-3 fatty acids for use as supplements during pregnancy and when breastfeeding are classified in V3X.
---

<b>G3C</b>	<p><b>OESTROGENS, EXCLUDING G3A, G3E, G3F</b></p> <p>Oestrogens in combination with non-hormonal substances are classified here.</p> <p>Products containing a SERM in combination with an oestrogen and indicated for the short-term treatment of menopausal symptoms together with the prevention of osteoporosis are classified here.</p> <p>Includes transdermal patches and vaginal formulations containing oestrogens and intended for a systemic effect.</p> <p>Products containing parenteral conjugated oestrogens for uterine bleeding are classified in B2G.</p>	r2019
<b>G3D</b>	<p><b>PROGESTOGENS, EXCLUDING G3A, G3F</b></p> <p>Products containing progesterone in topical form (such as gel) for the relief of breast pain are classified in G2F.</p>	r2021
<b>G3E</b>	<b>ANDROGEN WITH FEMALE HORMONE COMBINATIONS</b>	
<b>G3F</b>	<b>OESTROGEN WITH PROGESTOGEN COMBINATIONS, EXCLUDING G3A</b>	
<b>G3G</b>	<b>GONADOTROPHINS, INCLUDING OTHER OVULATION STIMULANTS</b>	
<b>G3H</b>	Out of use; can be reused from 2009.	D2006
<b>G3J</b>	<p><b>SERMS (SELECTIVE OESTROGEN RECEPTOR MODULATORS)</b></p> <p>Included in this class are products that contain selective oestrogen receptor modulators, eg lasofoxifene, raloxifene. When primarily indicated for cancer, SERMs are classified in L2.</p> <p>Products containing a SERM in combination with an oestrogen and indicated for the short-term treatment of menopausal symptoms together with the prevention of osteoporosis are classified in G3C.</p>	r2015
<b>G3X</b>	<p><b>OTHER SEX HORMONES AND SIMILAR PRODUCTS</b></p> <p>Includes mammary extracts and other hormonal preparations for sexual disorders eg placenta extracts. Cyproterone acetate (tab 10mg) is classified here; higher doses (50 mg) and injectable forms are in L2B2 when used as cytostatics. Includes products containing tibolone.</p> <p>Products containing mifepristone are classified here if indicated as abortifacients alone, or with other indications, or in G3A6 if indicated for emergency contraception.</p> <p>Products containing ulipristal are classified here if indicated for uterine fibroids, or in G3A6 if indicated for emergency contraception.</p>	r2015

G4C4	<p><b>BPH alpha-antagonists and 5-ARIs, combinations</b></p> <p>Includes products containing an alpha-adrenergic antagonist and a 5-alpha testosterone reductase inhibitor. If one or more additional substances are included, then the product is classified in G4C7.</p>	I2012
G4C7	<p><b>BPH 5-ARIs and/or alpha-antagonists in combination with other substances</b></p> <p>Includes products containing eg tamsulosin with tolterodine, tamsulosin with a substance of natural origin, or tamsulosin with corticosteroids.</p>	r2020
G4C8	Out of use	D2012
G4C9	<p><b>BPH products, other</b></p> <p>Includes products of herbal or animal origin, as well as homeopathic products, for BPH. Products containing mepartricine, <i>Serenoa repens</i>, or <i>Pygeum africanum</i> are classified in G4C9 if indicated for BPH. This class also includes herbal products for improving prostatic health.</p> <p>Products containing PDE5 inhibitors for BPH only are classified here.</p>	r2021
<b>G4D</b>	<b>URINARY INCONTINENCE PRODUCTS</b>	I2007
G4D4	<p><b>Urinary incontinence products</b></p> <p>This group includes preparations for urinary incontinence eg those containing duloxetine, flavoxate, oxybutynin, tolterodine. Products of natural origin and homeopathic products are classified in G4D8.</p>	I2007
G4D8	<p><b>Urinary incontinence products of natural origin</b></p> <p>Includes products of herbal or animal origin, as well as homeopathic products, for urinary incontinence. Also includes collagen injections for incontinence.</p>	I2007

<b>G4E</b>	<p><b>ERECTILE DYSFUNCTION PRODUCTS</b></p> <p>Includes products for the treatment of male impotence.</p>	r2015
<b>G4E1</b>	<p><b>Erectile dysfunction products, PDE5 inhibitors</b></p> <p>Includes products containing PDE5 inhibitors, eg avanafil, mirodenafil, sildenafil, tadalafil, udenafil, vardenafil, etc, when indicated for the treatment of erectile dysfunction.</p> <p>Products containing sildenafil (oral 20mg) or tadalafil and indicated for pulmonary arterial hypertension (PAH) only are classified in C6B2. Products containing tadalafil and indicated for both erectile dysfunction and PAH are classified here.</p> <p>Products indicated for erectile dysfunction that contain a PDE5 inhibitor in combination with other substances are classified here.</p> <p>Products containing a PDE5 inhibitor in combination with other substances, and indicated for erectile dysfunction as well as other conditions, are classified here.</p> <p>Products containing PDE5 inhibitors for BPH only are classified in G4C9.</p>	r2021
<b>G4E9</b>	<p><b>Erectile dysfunction products, others</b></p> <p>Includes products containing eg alprostadil, apomorphine, etc when indicated for the treatment of erectile dysfunction. Products containing alprostadil for peripheral arterial occlusive disease only are classified in C4A1. Products containing alprostadil for erectile dysfunction only are classified here. Products containing alprostadil for patent ductus arteriosus only or for multiple indications are classified in C1X.</p> <p>In addition, includes products that contain substances of natural origin for erectile dysfunction.</p> <p>Products that do not contain a PDE5 inhibitor and are indicated for erectile dysfunction, together with other urological conditions, are classified here.</p>	r2021
<b>G4X</b>	<p><b>ALL OTHER UROLOGICAL PRODUCTS</b></p> <p>Includes products containing local anaesthetics used specifically for premature ejaculation.</p> <p>Products for erectile dysfunction are classified in G4E. Products for both erectile dysfunction and other urological conditions are also classified in G4E. Products for improving general sexual performance (not specifically erectile dysfunction) are classified here.</p>	r2015

<b>J5</b>	<b>ANTIVIRALS FOR SYSTEMIC USE</b>	R2018
<b>J5A</b>	Out of use; can be reused from 2001.	D1998
<b>J5B</b>	<b>ANTIVIRALS, OTHER</b>	R2018
	Includes systemic antivirals for herpes, influenza, viral respiratory conditions, etc. Excludes topical skin antivirals (D6D), topical ophthalmic antivirals (S1D), HIV antivirals (J5C), and hepatitis antivirals (J5D).	
J5B1	Out of use	D2018
J5B3	<b>Herpes antivirals</b>	I2008
	Products used against herpes virus infections, including specific systemic forms of products for cytomegalovirus infections (including CMV retinitis), are classified here. Products in topical ophthalmic forms for CMV retinitis are classified in S1D.	
J5B4	<b>Influenza antivirals</b>	r2021
	Includes products indicated specifically for influenza. Products containing favipiravir for influenza only are classified here. Products containing favipiravir for COVID-19 only are classified in J5B5. Products containing favipiravir for both influenza and COVID-19 are classified in J5B5.	
J5B5	<b>Respiratory antivirals excluding influenza products</b>	r2021
	Includes products indicated specifically for respiratory syncytial virus (RSV) infections. Also includes inhalation forms of ribavirin where no indication has been specified.	
	Products containing bamlanivimab, favipiravir, remdesivir, etc specifically for COVID-19 are classified here. Products containing favipiravir for influenza only are classified in J5B4. Products containing favipiravir for both influenza and COVID-19 are classified here.	
	Products containing levilimab for use in COVID-19 are classified in L4C.	
J5B9	<b>Antivirals, others</b>	I2008
	Includes products containing lysozyme for viral infections.	

<p><b>J5C</b></p>	<p><b>HIV ANTIVIRALS</b></p> <p>Includes antiviral products specifically used to treat HIV (human immunodeficiency virus).</p> <p>Combinations of different classes of HIV antivirals are classified in J5C9. Combinations of HIV antivirals from a single class are classified in that relevant specific class, eg a product containing only two nucleoside reverse transcriptase inhibitors is classified in J5C1.</p> <p>Pentamidine isethionate which is used to treat <i>Pneumocystis carinii</i> in AIDS is classified in P1G.</p> <p>Products containing dapivirine (vaginal ring) for the prevention of HIV transmission are classified in G1D.</p>	<p>r2021</p>
<p><b>J5C1</b></p>	<p><b>Nucleoside and nucleotide reverse transcriptase inhibitors</b></p> <p>Includes abacavir, didanosine, emtricitabine, lamivudine, stavudine, tenofovir disoproxil, zalcitabine, zidovudine. Single-ingredient products containing tenofovir disoproxil and indicated for either HIV and/or hepatitis are classified here.</p> <p>Products containing single-ingredient lamivudine or tenofovir alafenamide and for hepatitis B only are classified in J5D2.</p>	<p>r2018</p>
<p><b>J5C2</b></p>	<p><b>Protease inhibitors</b></p> <p>Includes amprenavir, atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, tipranavir.</p>	<p>r2011</p>
<p><b>J5C3</b></p>	<p><b>Non-nucleoside reverse transcriptase inhibitors</b></p> <p>Includes delavirdine, efavirenz, etravirine, nevirapine.</p>	<p>r2011</p>
<p><b>J5C4</b></p>	<p><b>HIV antivirals, entry inhibitors</b></p> <p>Includes products containing entry inhibitors such as enfuvirtide, maraviroc.</p>	<p>I2011</p>
<p><b>J5C5</b></p>	<p><b>HIV antivirals, integrase inhibitors</b></p> <p>Includes products containing integrase inhibitors eg dolutegravir, elvitegravir, raltegravir.</p>	<p>I2015</p>
<p><b>J5C9</b></p>	<p><b>HIV antivirals, other</b></p> <p>Includes combinations of different classes of HIV antivirals. Combinations of HIV antivirals from a single class are classified in that relevant specific class, eg a product containing only nucleoside reverse transcriptase inhibitors is classified in J5C1.</p> <p>Products containing cobicistat as a single ingredient are classified here. Products</p>	<p>r2018</p>

containing cobicistat in combination with HIV antivirals are classified in the appropriate class for the antivirals.	
--	--



<b>J7E</b>	<b>VIRAL VACCINES</b>	r2018
	Includes separate classes for vaccines against only one viral group. For vaccines against a combination of bacteria or viruses, see J7B.	
J7E1	<b>Influenza vaccines</b>	I2014
J7E2	<b>Varicella vaccines</b>	I2014
J7E3	<b>HPV (human papillomavirus) vaccines</b>	I2014
J7E4	<b>Hepatitis vaccines</b>	I2014
J7E5	<b>Rotavirus vaccines</b>	I2014
J7E6	<b>Coronavirus vaccines</b>	I2021
	Includes vaccines against COVID-19.	
J7E9	<b>All other viral vaccines</b>	I2014
	Includes all other vaccines against one viral group, eg Japanese encephalitis, measles, mumps, polio, rubella, rabies, tick-borne encephalitis, yellow fever.	
<b>J7F</b>	<b>PROTOZOAL VACCINES</b>	I2018
	Includes separate classes for vaccines against only one protozoal group. For vaccines against a combination of a protozoal group and/or other organisms, see J7B.	
J7F1	<b>Malaria vaccines</b>	I2018
J7F9	<b>All other protozoal vaccines</b>	I2018
<b>J7X</b>	<b>ALL OTHER VACCINE-LIKE PRODUCTS</b>	r2018
	Includes products containing infectious agents and/or their derivatives, eg lysates and extracts of bacteria, that are not strictly considered vaccines.	

<b>L1G</b>	<b>MONOCLONAL ANTIBODY ANTINEOPLASTICS</b>  Antineoplastic monoclonal antibodies against protein kinases are classified here and not in L1H.	R2019
<b>L1G1</b>	<b>Monoclonal antibody antineoplastics, CD20</b>  Includes products containing obinutuzumab, ofatumumab, rituximab, rituximab with hyaluronidase, etc.	I2019
<b>L1G2</b>	<b>Monoclonal antibody antineoplastics, VEGF/VEGFR</b>  Includes products containing bevacizumab, ramucirumab, etc.	I2019
<b>L1G3</b>	<b>Monoclonal antibody antineoplastics, HER-2</b>  Includes products containing margetuximab, pertuzumab, trastuzumab, trastuzumab deruxtecan, trastuzumab emtansine, etc.	r2021
<b>L1G4</b>	<b>Monoclonal antibody antineoplastics, EGFR</b>  Includes products containing cetuximab, necitumumab, nimotuzumab, panitumumab, etc.	I2019
<b>L1G5</b>	<b>Monoclonal antibody antineoplastics, PD-1/PD-L1</b>  Includes products containing atezolizumab, avelumab, cemiplimab, durvalumab, nivolumab, pembrolizumab, tislelizumab, etc.	I2019

L1G9	<p><b>Monoclonal antibody antineoplastics, other</b></p> <p>Includes antibodies with other targets including other CD targets, CTLA-4 (ipilimumab), etc.</p> <p>Includes antibody drug conjugates (ADCs) if not classified with the target class (brentuximab vedotin, gemtuzumab ozogamicin, inotuzumab ozogamicin).</p> <p>Includes radio-labelled antibodies (ibritumomab tiuxetan, tositumomab iodine-131).</p> <p>Includes alemtuzumab, blinatumomab, brentuximab vedotin, catumaxomab, daratumumab, dinutuximab, elotuzumab, gemtuzumab ozogamicin, ibritumomab tiuxetan, inotuzumab ozogamicin, ipilimumab, mogamulizumab, olaratumab, racotumomab, rovalpituzumab tesirine, siltuximab, tositumomab, tositumomab iodine-131, etc.</p> <p>Products containing alemtuzumab and indicated for cancer only are classified here. Products containing alemtuzumab and indicated for multiple sclerosis are classified in N7A.</p>	I2019
<b>L1H</b>	<p><b>PROTEIN KINASE INHIBITOR ANTINEOPLASTICS</b></p> <p>Antineoplastic monoclonal antibodies against protein kinases are classified in L1G.</p>	R2019
L1H1	<p><b>Protein kinase inhibitor antineoplastics, BCR-ABL</b></p> <p>Includes products containing bosutinib, dasatinib, imatinib, nilotinib, ponatinib, radotinib, etc.</p>	I2019
L1H2	<p><b>Protein kinase inhibitor antineoplastics, EGFR</b></p> <p>Includes products containing afatinib, dacomitinib, erlotinib, gefitinib, icotinib, olmutinib, osimertinib, varlitinib, etc.</p>	I2019
L1H3	<p><b>Protein kinase inhibitor antineoplastics, ALK</b></p> <p>Includes products containing alectinib, brigatinib, ceritinib, crizotinib, lorlatinib, etc.</p>	I2019
L1H4	<p><b>Protein kinase inhibitor antineoplastics, BRAF/MEK</b></p> <p>Includes products containing binimetinib, cobimetinib, dabrafenib, encorafenib, selumetinib, trametinib, vemurafenib, etc.</p>	I2019

L1H5	<p><b>Protein kinase inhibitor antineoplastics, CDK 4/6</b></p> <p>Includes products containing abemaciclib, palbociclib, ribociclib, etc. Products containing both ribociclib and letrozole are classified here.</p>	I2019
L1H6	<p><b>Protein kinase inhibitor antineoplastics, BTK</b></p> <p>Includes products containing acalabrutinib, ibrutinib, tirabrutinib, zanubrutinib, etc.</p>	I2021
L1H9	<p><b>Protein kinase inhibitor antineoplastics, other</b></p> <p>Includes all other protein kinase inhibitor antineoplastics, for example those inhibiting HER-2, JAK 1-2, Pi3K, etc.</p> <p>Includes, apatinib, axitinib, cabozantinib, erdafitinib, everolimus, idelalisib, lapatinib, lenvatinib, midostaurin, neratinib, nintedanib, pazopanib, regorafenib, ruxolitinib, sorafenib, sunitinib, temsirolimus, tivozanib, vandetanib, etc.</p> <p>Products containing nintedanib for idiopathic pulmonary fibrosis only are classified in R7D. Products containing nintedanib for cancer only are classified here. Products containing nintedanib for both cancer and idiopathic pulmonary fibrosis are classified in R7D.</p>	r2021
L1J	<p><b>PROTEASOME INHIBITOR ANTINEOPLASTICS</b></p> <p>Includes products containing proteasome inhibitors for neoplasms, eg bortezomib, carfilzomib, ixazomib, etc.</p>	I2018
L1X	<p><b>ALL OTHER ANTINEOPLASTICS</b></p>	R2018
L1X1	<p><b>Alternative preparations for cancer therapy</b></p> <p>Includes products derived from Viscum (mistletoe).</p>	r2018
L1X2	<p><b>Lidomide antineoplastics</b></p> <p>Includes products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers.</p> <p>Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified here. Products containing thalidomide for ENL only are classified in L4X.</p>	I2019
L1X3	<p><b>HDAC inhibitor antineoplastics</b></p> <p>Includes products containing HDAC inhibitors for neoplasms, eg belinostat,</p>	I2018

L1X4	<p>entinostat, panobinostat, romidepsin, tucidinostat, vorinostat, etc.</p> <p><b>PARP inhibitor antineoplastics</b></p> <p>Includes products containing niraparib, olaparib, rucaparib, talazoparib, veliparib, etc.</p>	I2019
------	---	-------

L1X5	<p><b>CAR T-cell therapy antineoplastics</b></p> <p>Includes products containing axicabtagene ciloleucel, tisagenlecleucel, etc.</p>	I2019
L1X8	<p><b>Photosensitisers for cancer therapy</b></p> <p>Includes products containing photosensitisers for use in cancer therapy, eg aminolaevulinic acid, methyl aminolaevulinate, methoxsalen, porfimer, talaporfin, temoporfin, etc.</p> <p>Products containing aminolaevulinic acid for actinic keratosis, basal cell carcinoma or Bowen syndrome are classified here. Products containing aminolaevulinic acid for use in diagnostic procedures are classified in T1X.</p> <p>Products containing methoxsalen for other skin conditions such as psoriasis or vitiligo are classified in the appropriate D classes.</p> <p>Products containing vertoporphin for macular degeneration are classified in S1P.</p>	r2019
L1X9	<p><b>All other antineoplastics</b></p> <p>Includes amsacrine, enzymes, estramustine, gallium nitrate, methylhydralazine, mitotane, procarbazine, substituted urea, tasonermin, vosaroxin. Also includes celecoxib for familial adenomatous polyposis (FAP).</p> <p>Products containing aflibercept for cancer are classified here. Products containing aflibercept for macular degeneration are classified in S1P.</p> <p>Includes products containing hedgehog pathway inhibitors, eg glasdegib, sonidegib, vismodegib, etc.</p> <p>Products containing BCG vaccine for cancer are classified here; those for general immunostimulation are classified in L3A9. Products containing BCG vaccine for active immunisation against tuberculosis are classified in J7D6.</p>	r2020

<b>L3</b>	<b>IMMUNOSTIMULATING AGENTS</b>	I1994
<b>L3A</b>	<b>IMMUNOSTIMULATING AGENTS EXCLUDING INTERFERONS</b>	R2004
L3A1	<b>Colony-stimulating factors</b>  Includes aneastim, empegfilgrastim, filgrastim, lenograstim, molgramostim, pegfilgrastim, sargramostim.	r2018
L3A9	<b>All other immunostimulating agents excluding interferons</b>  Includes cridanimod, glatiramer acetate, interleukin-2, picibanil.  <i>Corynebacterium parvum</i> and levamisole are classified here when used as immunostimulants.  Products containing BCG vaccine for cancer are classified in L1X9; those for general immunostimulation are classified here. Products containing BCG vaccine for active immunisation against tuberculosis are classified in J7D6.  Products containing elapegademas or pegademas for severe combined immunodeficiency disease (SCID) associated with a deficiency of adenosine deaminase are classified here.	r2021
<b>L3B</b>	<b>INTERFERONS</b>  Products containing interferons (with or without ribavirin) for multiple indications are classified in L3B. Products containing interferons (with or without ribavirin) for hepatitis only are classified in J5D1.	r2018
L3B1	<b>Interferons, alpha</b>	I1994
L3B2	<b>Interferons, beta</b>  Products containing beta interferons and indicated for multiple sclerosis only are classified in N7A. Products containing beta interferons and indicated for both multiple sclerosis and other conditions are classified here.	R2017
L3B3	<b>Interferons, gamma</b>	I1994
L3B9	<b>Interferons, non-specified</b>	I1994

<b>L4</b>	<b>IMMUNOSUPPRESSANTS</b>	R2010
<b>L4A</b>	Out of use; can be reused from 2013.	D2010
<b>L4B</b>	<b>ANTI-TNF PRODUCTS</b>  Products containing anti-TNF substances are classified here, eg adalimumab, afelimomab, certolizumab pegol, etanercept, golimumab, infliximab. These products can be indicated for multiple conditions, eg rheumatoid arthritis, Crohn's disease, psoriasis.  Products containing apremilast for psoriatic conditions only are classified in D5B. Products containing apremilast for multiple conditions are classified in L4X.	r2020
<b>L4C</b>	<b>INTERLEUKIN INHIBITORS</b>  Includes products containing interleukin inhibitors, eg basiliximab, canakinumab, daclizumab, rilonacept.  Includes interleukin inhibitors indicated for the treatment of rejection in organ transplants and for auto-inflammatory diseases such as CAPS (cryopyrin-associated periodic syndromes).  Products containing tocilizumab or anakinra and indicated for arthritic conditions are classified in M1C. Products containing tocilizumab and indicated for both arthritic conditions and also giant cell arteritis are classified in M1C. Products containing brodalumab, ixekizumab, secukinumab or ustekinumab and indicated for skin conditions such as psoriasis and also other non-skin conditions, eg rheumatoid arthritis, are classified here. Psoriatic arthritis is defined as a skin condition.  Products containing daclizumab and indicated for use in kidney transplantation are classified here. Products containing daclizumab and indicated for multiple sclerosis and other conditions are classified in N7A.  Products containing mepolizumab for asthma only or for asthma and EGPA (eosinophilic granulomatosis with polyangiitis) are classified in R3M.  Products containing dupilumab for atopic dermatitis are classified in D5X. Products containing dupilumab for both atopic dermatitis and asthma are classified here.  Products containing levilimab for use in COVID-19 are classified here.	r2021



<b>L4X</b>	<p data-bbox="316 136 834 165"><b>OTHER IMMUNOSUPPRESSANTS</b></p> <p data-bbox="316 215 1393 282">Immunosuppressants used in the treatment of rejection in organ transplants are classified here, or in L4C if they contain interleukin inhibitors.</p> <p data-bbox="316 324 1393 499">Includes eg antilymphocyte and antithymocyte immunoglobulins, azathioprine, cyclosporin, muromonab-cd3, mycophenolate mofetil, tacrolimus – unless classified elsewhere because of a specific indication or formulation. For example, ophthalmic cyclosporin for dry eye is classified in S1K9 and dermatological tacrolimus is classified in D5X.</p> <p data-bbox="316 542 1393 645">Products for multiple sclerosis are classified in N7A. Products containing natalizumab and indicated for multiple sclerosis and other conditions are classified in N7A.</p> <p data-bbox="316 687 1393 790">Products containing apremilast for psoriatic skin conditions only, are classified in D5B. Psoriatic arthritis is defined as a skin condition. Products containing apremilast for multiple conditions are classified here.</p> <p data-bbox="316 833 1393 1008">Products containing lenalidomide, pomalidomide or thalidomide for multiple myeloma and other cancers are classified in L1X2. Products containing thalidomide for both cancer and erythema nodosum leprosum (ENL) are classified in L1X2. Products containing thalidomide for erythema nodosum leprosum only are classified here.</p> <p data-bbox="316 1050 1393 1122">Products containing tofacitinib for multiple conditions are classified here. Products containing tofacitinib for rheumatoid arthritis only are classified in M1C.</p> <p data-bbox="316 1164 1393 1267">Products containing leflunomide for multiple conditions are classified here. Products containing leflunomide for rheumatoid arthritis only are classified in M1C.</p> <p data-bbox="316 1310 1393 1382">Products containing baricitinib for multiple conditions are classified here. Products containing baricitinib for rheumatoid arthritis only are classified in M1C.</p> <p data-bbox="316 1424 810 1453">Corticosteroids are not classified here.</p>	r2021
------------	---	-------

<b>M1C</b>	<p><b>SPECIFIC ANTI-RHEUMATIC AGENTS</b></p> <p>This class includes abatacept, anakinra, tocilizumab, gold preparations, bucillamine, penicillamine and quinolines (eg oxycinchophen). Includes products containing mesalazine, olsalazine, and sulphasalazine if specifically indicated for rheumatic conditions. Products containing aminosalicylates and used for intestinal inflammatory conditions, are classified in A7E1.</p> <p>Azathioprine is in L4X. Products containing methotrexate for rheumatic conditions are classified here; otherwise methotrexate is classified in LIB or in D.</p> <p>Products containing anti-TNF substances are classified in L4B.</p> <p>Products containing tofacitinib, and indicated for rheumatoid arthritis only, are classified here. Products containing tofacitinib for multiple conditions are classified in L4X.</p> <p>Products containing leflunomide, and indicated for rheumatoid arthritis only, are classified here. Products containing leflunomide for multiple conditions are classified in L4X.</p> <p>Products containing interleukin inhibitors and only indicated for arthritic conditions are classified here, eg anakinra. Products containing tocilizumab and indicated for both arthritis and giant cell arteritis are classified here. Other interleukin inhibitors indicated for multiple conditions including arthritis are classified in L4C.</p> <p>Products containing baricitinib, and indicated for rheumatoid arthritis only, are classified here. Products containing baricitinib for multiple indications are classified in L4X.</p> <p>Psoriatic arthritis is defined as a skin condition.</p>	r2021
------------	---	-------

<b>M5X</b>	<p><b>ALL OTHER MUSCULOSKELETAL PRODUCTS</b></p> <p>Includes all other products for disorders of the musculoskeletal system not classified elsewhere. Includes musculoskeletal products containing substances such as cartilage extract, chondroitin, etc. Products containing chondroitin and glucosamine alone or in combination with other substances are classified here. Combinations of glucosamine with nonsteroidal anti-inflammatories are classified in M1A2. Topical glucosamine and chondroitin products are classified in M2A.</p> <p>Includes hydroquinine indicated for restless leg syndrome.</p> <p>Includes herbal products used for musculoskeletal pain.</p> <p>Products containing burosumab for X-linked hypophosphataemia are classified here.</p> <p>Products containing mexiletine for non-dystrophic myotonic disorders are classified here; products containing mexiletine for cardiac arrhythmias are classified in C1B .</p> <p>Products containing diclofenamide for primary periodic paralysis are classified here. Products containing diclofenamide for glaucoma are classified in S1E1. Products containing diclofenamide for diuretic use are classified in C3A9.</p>	r2021
------------	--	-------

<p><b>N7E</b></p>	<p><b>DRUGS USED IN ALCOHOL DEPENDENCE</b></p> <p>Includes acamprosate, calcium carbimide, disulfiram. Naltrexone when used in alcohol dependence is classified here.</p>	<p>R2002</p>
<p><b>N7F</b></p>	<p><b>DRUGS USED IN OPIOID DEPENDENCE</b></p> <p>Includes naltrexone, except when used in alcohol dependence (use N7E).</p>	<p>R2002</p>
<p><b>N7X</b></p>	<p><b>ALL OTHER CNS DRUGS</b></p> <p>Includes parasympathetic agents. Benzodiazepine antagonists such as flumazenil are classified here. Atomoxetine is included in the class. Products containing gabapentin or pregabalin are classified in N3A if indicated for both neuropathic pain and epilepsy.</p> <p>Products containing pilocarpine and indicated for both dry mouth and dry eye are classified here.</p> <p>Products indicated for multiple sclerosis are classified in N7A. Products containing fampridine for improvement in walking in multiple sclerosis are classified here.</p> <p>Products indicated for amyotrophic lateral sclerosis (ALS) are classified here.</p> <p>Products containing tafamidis for transthyretin amyloid polyneuropathy (TAP) only are classified here. Products containing tafamidis for transthyretin amyloid cardiomyopathy (TAC) only are classified in C1X. Products containing tafamidis for both TAP and TAC are classified here.</p> <p>Products containing inebilizumab or satralizumab for neuromyelitis optica spectrum disorder (NMOSD) are classified here.</p>	<p>r2021</p>

<b>R5</b>	<b>COUGH AND COLD PREPARATIONS</b>	
<b>R5A</b>	<b>COLD PREPARATIONS WITHOUT ANTI-INFECTIVES</b>	R1994
	This group consists of all products indicated for colds, influenza, etc. It therefore includes combination products such as those containing antihistamines with decongestants, analgesics, antipyretics, vitamins, etc and since symptoms of colds and influenza may include a cough, an antitussive, and possibly an expectorant may also be included (see also R5D2 and R5C).	
<b>R5B</b>	<b>COUGH/COLD PREPARATIONS WITH ANTI-INFECTIVES</b>	r2016
	Includes combinations with anti-infectives (including antivirals) indicated specifically for coughs, colds, influenza and other respiratory conditions. Combinations of antiseptics with expectorants are classified in R5C and with antitussives are classified in R5D2.	
<b>R5C</b>	<b>EXPECTORANTS</b>	r2021
	'Expectorants' mean substances with secretolytic or secretomotoric activity, so that mucolytics are classified in this group.	
	The group includes all cough preparations with an expectorant as the main ingredient (eg guaiacol, saponin, ammonium chloride). These may also include antihistamines and bronchodilators but excluded are combinations of expectorants with antitussives (R5D2), with analgesics and antipyretics (R5A), and with anti-infectives (R5B). Lozenges indicated for cough and containing expectorants are classified here. Products containing dornase alfa for cystic fibrosis are classified here.	
<b>R5D</b>	<b>ANTITUSSIVES</b>	
<b>R5D1</b>	<b>Plain antitussives</b>	
	Includes all plain antitussives.	
<b>R5D2</b>	<b>Antitussives in combinations</b>	R1994
	Includes combinations with expectorants, antihistamines, ephedrine, herbal tinctures, etc. Excluded are combinations with analgesics and antipyretics (R5A) and combinations with anti-infectives (R5B).	
<b>R5E</b>	Out of use; can be reused.	

<b>R7</b>	<b>OTHER RESPIRATORY SYSTEM PRODUCTS</b>	
<b>R7A</b>	<b>RESPIRATORY STIMULANTS</b>  Includes centrally acting respiratory stimulants such as lobeline, ethamivan, crotetiamide, croptopamide, nikethamide and doxapram (plain only).  Also includes products specifically indicated for primary apnoea in premature newborn babies.	R2006
<b>R7B</b>	<b>CYSTIC FIBROSIS PRODUCTS</b>  Products containing dornase alfa for cystic fibrosis are classified in R5C.	I2021
<b>R7B1</b>	<b>Cystic fibrosis transmembrane regulator (CFTR) modulators</b>  Includes products containing eg elexacaftor, ivacaftor, lumacaftor, tezacaftor, etc for cystic fibrosis.	I2021
<b>R7C</b>	<b>LUNG SURFACTANTS</b>  Includes substances such as colfoscaril palmitate used in neonatal respiratory distress syndrome.	I1996
<b>R7D</b>	<b>IDIOPATHIC PULMONARY FIBROSIS PRODUCTS</b>  Includes products containing eg pirfenidone, nintedanib, etc for idiopathic pulmonary fibrosis.  Products containing nintedanib for idiopathic pulmonary fibrosis only are classified here. Products containing nintedanib for cancer only are classified in L1H9. Products containing nintedanib for both cancer and idiopathic pulmonary fibrosis are classified here.	I2021
<b>R7X</b>	<b>ALL OTHER RESPIRATORY SYSTEM PRODUCTS</b>	r2021

<b>S</b>	<b>SENSORY ORGANS</b>	
<b>S1</b>	<b>OPHTHALMOLOGICALS</b>	
<b>S1A</b>	<b>OPHTHALMOLOGICAL ANTI-INFECTIVES</b>	r2009
	Includes plain anti-infectives (antibacterials eg sulphonamides, and antifungals) and all anti-infective combinations with the exception of corticosteroid/anti-infective combinations (S1C). Also excluded are antiseptics (S1G6) and antivirals (S1D).	
<b>S1B</b>	<b>OPHTHALMOLOGICAL CORTICOSTEROIDS</b>	
	Includes plain corticosteroids and all corticosteroid combinations, with the exception of corticosteroid/anti-infective combinations (S1C).	
<b>S1C</b>	<b>OPHTHALMOLOGICAL ANTI-INFLAMMATORY/ANTI-INFECTIVE COMBINATIONS</b>	R2001
S1C1	<b>Ophthalmological corticosteroid and anti-infective combinations</b>	I2001
S1C2	<b>Ophthalmological NSAIDS and anti-infective combinations</b>	I2001
S1C9	<b>Other ophthalmological anti-inflammatory and anti-infective combinations</b>	I2001
<b>S1D</b>	<b>OPHTHALMOLOGICAL ANTIVIRAL AGENTS</b>	r2008
	Includes aciclovir, iododesoxycytidine, idoxuridine, 5-ethyl-2' deoxyuridine, trifluridine, tromantadine, vidarabine. Systemic forms of products for cytomegalovirus retinitis are classified in J5B3.	
<b>S1E</b>	<b>MIOTICS AND ANTIGLAUCOMA PREPARATIONS</b>	
S1E1	<b>Miotics and antiglaucoma preparations, systemic</b>	r2021
	Includes carboanhydrase inhibitors (acetazolamide, diclofenamide and methazolamide), only when they are specifically promoted and used for the treatment of glaucoma (see also C3A9). Products containing diclofenamide for primary periodic paralysis are classified in M5X and for diuretic use are classified in C3A9.	
S1E2	<b>Miotics and antiglaucoma preparations, topical</b>	R2007
	Includes parasympathomimetics (acelidine, acetylcholine, clonidine, pilocarpine); anticholinesterases or cholinesterase inhibitors (carbachol, demecarium bromide, distigmine, ecothiopate iodide, isofluorophate (DFP), neostigmine, paraoxon, physostigmine); sympathicolitics (guanethidine); beta-blockers (bupranolol, timolol); sympathomimetics (adrenaline/epinephrine); prostaglandin analogues; carbo-anhydrase inhibitors.	

<b>V3</b>	<b>ALL OTHER THERAPEUTIC PRODUCTS</b>	
<b>V3A</b>	Out of use; can be reused from 2009.	D2006
<b>V3B</b>	<b>KANPO AND CHINESE MEDICINES</b>	
<b>V3B1</b>	<b>Kanpo medicines</b>	R2003
<b>V3B2</b>	<b>Chinese medicines</b>	R2003
<b>V3C</b>	<b>RADIOPHARMACEUTICALS</b>	R2003
	<p>This group includes medical products which are registered on the Japanese pharmacopoeia and radioactive medicament standard and also includes combination products with radioactive nucleus prescribed by standard provisions.</p> <p>This group excludes products used as diagnostics (see T1).</p> <p>Strontium-89 and similar substances used to treat pain of bone metastases are classified here.</p>	
<b>V3D</b>	<b>DETOXIFYING AGENTS FOR ANTINEOPLASTIC TREATMENT</b>	R2005
	Includes amifostine, calcium folinate, calcium levofolate, dexrazoxane, and mesna when indicated for adjuvant therapy in antineoplastic treatment. Products containing calcium folinate and which have multiple indications are classified here.	
<b>V3E</b>	<b>ANTIDOTES</b>	R2007
	Includes products containing eg dimercaprol, edetates, methionine, protamine, pralidoxime. Zinc acetate for Wilson's disease is classified here.	
<b>V3F</b>	<b>IRON-CHELATING AGENTS</b>	I2006
	Includes products containing eg deferiprone, deferoxamine.	
<b>V3G</b>	<b>HYPERKALAEMIA/HYPERPHOSPHATAEMIA PRODUCTS</b>	R2016
<b>V3G1</b>	<b>Hyperkalaemia products</b>	I2016
	Includes products used specifically for hyperkalaemia, eg those containing calcium polystyrene sulfonate, sodium polystyrene sulfonate, patiromer calcium etc.	



V3G2	<p><b>Hyperphosphataemia products</b></p> <p>Includes products used specifically for hyperphosphataemia, eg those containing bixalomer, calcium acetate, calcium acetate in combination with magnesium carbonate, calcium carbonate, colestilan, ferric citrate, lanthanum carbonate, sevelamer, sucroferric oxyhydroxide, etc.</p> <p>Products containing calcium and indicated in both hyperphosphataemia and calcium deficiency are classified in V3G2.</p>	I2016
V3H	<p><b>ANTI-INFLAMMATORY ENZYMES</b></p> <p>This group includes all enzyme preparations which are indicated to treat inflammatory conditions. Includes enzyme preparations for respiratory conditions. Excluded are enzyme preparations used in digestive conditions which are classified in A9A. Also excluded are specific cholagogues - classified in A5A, enzymatic topical wound treatments - classified in D3A, enzymes for ophthalmic use - classified in S1S9.</p>	R2007
V3X	<p><b>ALL OTHER THERAPEUTIC PRODUCTS</b></p> <p>Includes products with multiple anatomical effects, not readily classifiable in any single group. Large packs of chemicals (bulk packs) which are intended for preparation of formulations in the pharmacy/laboratory are classified here. Kelp products are classified here. Includes medical oxygen cylinders.</p> <p>Products containing omega-3 fatty acids for the reduction of triglycerides and/or the prevention and treatment of arteriosclerosis are classified in C10B. Products containing omega-3 fatty acids for other conditions (including supplementation in pregnancy and breastfeeding) or for multiple uses are classified here.</p> <p>4<sup>th</sup> level used only in Germany and Hungary.</p>	r2021
V3X1	<p><b>Umstimmungsmittel preparations of herbal origin</b></p> <p>Products which are said to intensify the body's defence against infection.</p>	I2006
V3X4	<p><b>Cure-all preparations</b></p> <p>These products have a broad spectrum of indications for internal and external use. Includes products containing a mixture of homeopathic together with allopathic or herbal ingredients. These products can have several indications.</p>	I2006
V3X5	<p><b>Homeopathic preparations (1)</b></p> <p>Includes single homeopathic dilutions named after the homeopathic ingredient (eg belladonna D3) and complex series. These products can have several indications or the indication is not specified.</p>	I2006

V3X6	<p><b>Homeopathic preparations (2)</b></p> <p>Includes homeopathic specialities with a brand name and containing only homeopathic ingredients. These products can have several indications or the indication is not specified.</p>	I2006
V3X7	<p><b>Dried and cut plants for tea preparations</b></p> <p>These are packed for sale and have more than one indication, or they are standard registrations.</p>	I2006
V3X9	<p><b>Other therapeutic preparations</b></p>	I2006